Nektar Therapeutics (NASDAQ:NKTR) Director Lutz Lingnau sold 30,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $20.76, for a total transaction of $622,800.00. Following the completion of the transaction, the director now directly owns 53,450 shares in the company, valued at approximately $1,109,622. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Nektar Therapeutics (NASDAQ:NKTR) opened at 21.60 on Wednesday. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.88. The firm’s market capitalization is $3.35 billion. The company’s 50-day moving average is $19.50 and its 200-day moving average is $17.40.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.02. Nektar Therapeutics had a negative net margin of 150.74% and a negative return on equity of 3,072.86%. The company had revenue of $24.73 million for the quarter, compared to the consensus estimate of $29.43 million. During the same quarter last year, the business posted ($0.14) earnings per share. Nektar Therapeutics’s revenue was down 58.0% on a year-over-year basis. Equities analysts forecast that Nektar Therapeutics will post ($1.17) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Nektar Therapeutics (NASDAQ:NKTR) Director Lutz Lingnau Sells 30,000 Shares” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/07/19/nektar-therapeutics-nasdaqnktr-director-lutz-lingnau-sells-30000-shares.html.

Large investors have recently made changes to their positions in the stock. Aperio Group LLC raised its stake in shares of Nektar Therapeutics by 11.0% in the second quarter. Aperio Group LLC now owns 43,347 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 4,290 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock valued at $1,236,000 after buying an additional 500 shares in the last quarter. LS Investment Advisors LLC raised its stake in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Nektar Therapeutics by 79.6% in the second quarter. State of Alaska Department of Revenue now owns 30,625 shares of the biopharmaceutical company’s stock valued at $598,000 after buying an additional 13,575 shares in the last quarter. Finally, Piedmont Investment Advisors LLC acquired a new stake in shares of Nektar Therapeutics during the first quarter valued at about $216,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on NKTR shares. William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a research note on Monday, June 26th. Jefferies Group LLC set a $25.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Saturday, April 22nd. Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 27th. ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Roth Capital set a $31.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 11th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $25.25.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.